Lei Kang

6.2k citations
184 papers · 4.4k indexed · h-index 38
Topics
Monoclonal and Polyclonal Antibodies Research (22 papers)Radiopharmaceutical Chemistry and Applications (21 papers)Peptidase Inhibition and Analysis (16 papers)

In The Last Decade

Lei Kang

163 papers receiving 4.4k citations

Peers

Lei Kang
Comparison fields: 5 of 164
  • Molecular Biology 1.6k
  • Biomedical Engineering 1.0k
  • Cancer Research 861
  • Oncology 643
  • Materials Chemistry 508
Replace Yuan Wang with:
Yuan Wang China
Xiaohong Li China
Chang Liu China
Junhua Wu China
Chul‐Kee Park South Korea
Jun Huang China
Jianru Xiao China
Jin Chen China
Ping Gu China
Yasuhiro Nakamura Japan
Lei Kang relative to Yuan Wang China Yuan Wang's profile →
Citations per field
00.5×1.5×2.2×
Yuan Wang · 1×
Citations per year

Countries citing papers authored by Lei Kang

Since Specialization
Citations

This map shows the geographic impact of Lei Kang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lei Kang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lei Kang more than expected).

Fields of papers citing papers by Lei Kang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lei Kang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lei Kang. The network helps show where Lei Kang may publish in the future.

Co-authorship network of co-authors of Lei Kang

This figure shows the co-authorship network connecting the top 25 collaborators of Lei Kang. A scholar is included among the top collaborators of Lei Kang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lei Kang. Lei Kang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 7
4 0
5 7
6 7
7 4
8 8
9 1
10 1
11 1
12 3
13 1
14 69
15 115
16 1
17
Hsa_circ_0001806 Acts as a ceRNA to Facilitate the Stemness of Colorectal Cancer Cells by Increasing COL1A1
1
18 1
19 0
20 225

About Lei Kang

Lei Kang is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Cancer Research, having authored 184 papers that have together received 4.4k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (22 papers), Radiopharmaceutical Chemistry and Applications (21 papers) and Peptidase Inhibition and Analysis (16 papers). The work is most often cited by research in Cancer Research (861 citations), Molecular Biology (1.6k citations) and Oncology (643 citations). Lei Kang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Weibo Cai, Xiaojie Xu, Dawei Jiang, Yin Long, Jun Li, Xudong Wang, Zhongyi Fan, Qinong Ye, Guang Yao and Jonathan W. Engle. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Advanced Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026